A new study of cognitively healthy older women has found that longer lifetime exposure to estrogen, through both natural reproductive factors and hormone therapies, correlates with markers of healthier brain aging. The research, published in the journal Neurology, examined brain MRI scans from 352 Swedish women around age 70 and identified links between extended estrogen exposure and lower burdens of cerebral small vessel disease along with preserved white matter integrity.
Neurobiologist Anna Marseglia of the Karolinska Institutet led the work, which drew on data from the Gothenburg H70 birth cohort. Women with longer reproductive spans, measured from first menstruation to menopause, showed an 8 percent lower odds of having two or more signs of small vessel disease. Those who had used menopausal hormone therapy exhibited even stronger associations, with 59 percent lower odds of elevated small vessel disease burden and better white matter integrity on imaging.
The most favorable profiles appeared among women who had used both oral contraceptives earlier in life and menopausal hormone therapy later. These participants showed the lowest small vessel disease burden and the greatest white matter integrity. Marseglia noted that hormonal factors across different life stages may have cumulative associations with cerebrovascular health in older age.
Broader Context on Estrogen and Brain Health
Women face roughly twice the lifetime risk of Alzheimer’s disease compared with men, a disparity that has prompted researchers to examine the role of reproductive hormones. Estrogen influences brain regions involved in memory, including the hippocampus and prefrontal cortex, and supports processes such as glucose metabolism and synaptic function. The sharp drop in circulating estradiol at menopause has been linked in prior work to accelerated brain aging markers.
Earlier observational studies have produced mixed results on hormone therapy. Some analyses of large cohorts have associated estrogen-only menopausal hormone therapy with lower dementia risk and fewer Alzheimer’s-related brain changes at autopsy. One analysis of more than 21,000 participants found hormone therapy users had 39 percent lower odds of a dementia diagnosis and 35 percent lower odds of advanced Alzheimer’s pathology, including amyloid plaques and tau tangles, at death. The study, published in Neurology by the American Academy of Neurology, focused on estrogen-only formulations and noted that participants began therapy on average after age 70.
Separate research has examined lifetime estrogen exposure through additional lenses. A University of Kansas study of 459 women aged 65 to 80 linked use of hormonal birth control in young adulthood, later menopausal hormone therapy, and later natural menopause to larger brain volumes and thicker cortex in memory-related regions. Combined use of birth control and menopausal hormone therapy correlated with greater volume in parietal and temporal areas.
Additional Recent Findings
Autopsy and biomarker data have added further detail. Researchers at Stanford Medicine reviewed records from nearly 3,000 deceased women and found that those who had used estrogen-only hormone therapy showed lower odds of advanced Alzheimer’s pathology and fewer signs of cerebrovascular disease. The protective signal appeared strongest with conjugated estrogens. Women using the therapy also performed better on memory tests.
Animal models have explored mechanisms. A Northwestern University study in mice demonstrated that loss of brain-derived estrogen in older females triggered memory impairments and changes in hippocampal extracellular matrix not seen in males, suggesting sex-specific sensitivity to estrogen decline in the brain.
Smaller human studies have looked at symptom relief. A UCLA Health case series of 20 menopausal women reported that a regimen combining estriol and progesterone was associated with reductions in self-reported brain fog, concentration difficulties, and declines in working memory and processing speed after 12 months.
Limitations and Next Steps
Researchers emphasize that these findings are observational and do not establish causation. Factors such as socioeconomic status, education, genetics including APOE4 status, and overall health behaviors could influence both hormone therapy decisions and brain outcomes. The Marseglia study participants were cognitively healthy at enrollment, limiting generalizability to those already showing decline.
Timing of exposure remains a key area of inquiry. Some evidence supports a “critical window” around the menopause transition for potential benefits, while other data suggest associations with exposure across the lifespan. Randomized controlled trials are needed to clarify whether initiating or extending hormone therapy in later life could meaningfully alter trajectories of cognitive aging or dementia risk.
Public health implications could be substantial given the aging population and the disproportionate burden of Alzheimer’s disease on women. If confirmed, the results might inform discussions between clinicians and patients about hormone therapy options, particularly for those with longer or shorter reproductive spans. Ongoing work is examining molecular signatures of menopause in blood proteins and their ties to brain aging pathways.
Scientists continue to investigate how estrogen interacts with inflammation, vascular health, and amyloid and tau pathology. The recent wave of studies, including the Karolinska-led analysis of vascular markers, adds nuance to longstanding debates and underscores the value of considering cumulative hormone exposure when studying women’s brain health across the lifespan.
